Clarissa Desjardins Net Worth

Clarissa Desjardins biography

Dr. Clarissa Desjardins Ph.D. serves as Independent Director of the Company., with effective 14 November 2019. Since founding Clementia in 2011, Dr. Desjardins has served as the company's Chief Executive Officer. Prior to Clementia, she was Chief Executive Officer and a member of the board of directors at the Centre of Excellence in Personalized Medicine (CEPMED), a Montreal -based federally and privately funded non-profit enterprise created to promote personalized medicine. In 1998, Dr. Desjardins co-founded Caprion Pharmaceuticals, a biotechnology company focused on proteomic biomarker discovery and drug development, where she was Senior Vice President of Corporate Development and served on the board of directors. Dr. Desjardins also founded Advanced Bioconcept, a research reagent and diagnostics company, in 1992, which was sold to NEN Life Sciences (since acquired by PerkinElmer) in 1998. Dr. Desjardins earned a doctorate in neurology and neurosurgery from McGill University's Faculty of Medicine and was a Medical Research Council postdoctoral fellow at the Douglas Hospital Research Centre at McGill University . She currently serves on the Board of Directors for BELLUS Health Inc. Dr. Desjardins has more than 20 years of leadership experience in biotechnology, pharmaceuticals and research. The Board believes that Dr. Desjardins' skills, including her unique experience in the founding of several pharmaceutical and biotechnology companies, leadership roles, corporate development expertise, public company experience and medical education, make her a valuable asset to the Board.

What is the salary of Clarissa Desjardins?

As the Independent Director of Insmed Inc, the total compensation of Clarissa Desjardins at Insmed Inc is $107,346. There are 18 executives at Insmed Inc getting paid more, with William Lewis having the highest compensation of $7,175,090.

How old is Clarissa Desjardins?

Clarissa Desjardins is 53, he's been the Independent Director of Insmed Inc since 2019. There are 11 older and 10 younger executives at Insmed Inc. The oldest executive at Insmed Inc is Steinar Engelsen, 70, who is the Independent Director.

What's Clarissa Desjardins's mailing address?

Clarissa's mailing address filed with the SEC is 700 US HIGHWAY 202/206, , BRIDGEWATER, NJ, 08807.

Insiders trading at Insmed Inc

Over the last 22 years, insiders at Insmed Inc have traded over $46,121,705 worth of Insmed Inc stock and bought 1,080,212 units worth $8,226,993 . The most active insiders traders include Llc Fmr, William Lewis, eDennis M Lanfear. On average, Insmed Inc executives and independent directors trade stock every 38 days with the average trade being worth of $2,452,158. The most recent stock trade was executed by Orlov S Nicole Schaeffer on 10 September 2024, trading 37,575 units of INSM stock currently worth $407,689.

What does Insmed Inc do?

insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. the company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. headquartered in bridgewater, nj, we are a rapidly growing company with offices in seven countries.

Insmed Inc executives and stock owners

Insmed Inc executives and other stock owners filed with the SEC include:

• William Lewis,
  Chairman of the Board, President, Chief Executive Officer
• Roger Adsett,
  Chief Operating Officer
• Christine Pellizzari,
  Chief Legal Officer
• S. Nicole Schaeffer,
  Chief People Strategy Officer
• William H. Lewis J.D., M.B.A.,
  Pres, CEO & Chairman
• Dr. Martina Flammer M.B.A., M.D.,
  Chief Medical Officer
• John Goll,
  Chief Accounting Officer
• Roger Adsett,
  Chief Operating Officer
• Christine A. Pellizzari J.D.,
  Consultant
• Sara M. Bonstein MBA,
  Chief Financial Officer
• John Goll III,
  Sr. VP & Chief Accounting Officer
• David Brennan,
  Lead Independent Director
• Alfred Altomari,
  Independent Director
• Steinar Engelsen,
  Independent Director
• David McGirr,
  Independent Director
• Melvin Sharoky,
  Independent Director
• Leo Lee,
  Independent Director
• Elizabeth Anderson,
  Independent Director
• Clarissa Desjardins,
  Independent Director
• Carol Schafer,
  Director
• Martina Flammer,
  Chief Medical Officer
• John Soriano,
  Chief Compliance Officer
• Sara Bonstein,
  Chief Financial Officer
• S. Nicole Schaeffer,
  Chief People Strategy Officer
• Mandy Fahey,
  Sr. Director of Corp. Communications
• Michael Alexander Smith,
  Sr. VP & Gen. Counsel
• John D. Soriano J.D.,
  Chief Compliance Officer
• Eleanor Barisser,
  Associate Director of Investor Relations
• Paolo Tombesi,
  Chief Financial Officer
• Paul Streck,
  Chief Medical Officer
• Eugene Jeffrey Sullivan,
  Chief Medical Officer
• Myrtle S Potter,
  Director
• Donald J Jr Hayden,
  Director
• Geoffrey Allan,
  President, CEO and Chairman
• Stephen C. Glover,
  President Follow-on Biologics
• Doug Farrar,
  Vice President, ITP
• Michael Duncan,
  Principal Financial Officer
• Thomas A Keuer,
  VP, ITP (Subsidiary)
• Philip J Young,
  Chief Business Officer and EVP
• Ronald D Gunn,
  Executive Vice President
• Mark Quigley,
  Vice President, Quality
• Randall W Whitcomb,
  Director
• Peggy Berry,
  Vice President, Regulatory
• Renu Gupta,
  Chief Medical Officer
• Richard S Kollender,
  Director
• Matthew Pauls,
  Chief Commercial Officer
• Llc Fmr,
  10% owner
• Andrea Holtzman Drucker,
  Senior V.P., General Counsel
• Nicholas A. Jr. La Bella,
  Chief Scientific Officer
• Kenneth G Condon,
  Director
• Kevin P Tully,
  Executive VP & CFO
• Timothy Whitten,
  President & CEO
• Graham K Crooke,
  Director
• Nicholas Lee Gurreri,
  Senior VP, Commercial Ops
• Dennis M Lanfear,
  Director
• John Drayton Wise,
  Chief Commercial Officer
• Michael Alexander Smith,
  Chief Legal Officer